Medications

FDA approves drug combo for metastatic non-small cell lung cancer

The U.S. Food and Drug Administration approved the combination of tremelimumab (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing ...

Medications

Update shows relatlimab + nivolumab slows advanced melanoma

For patients with previously untreated metastatic or unresectable melanoma, the combination of relatlimab + nivolumab continues to demonstrate a progression-free survival (PFS) benefit over nivolumab alone, according to updated ...

Medications

Lenvatinib + pembrolizumab treats advanced endometrial cancer

(HealthDay)—For patients with advanced endometrial cancer, lenvatinib plus pembrolizumab results in significantly longer progression-free and overall survival than the physician's choice of chemotherapy, according to a ...

Medications

Combo immunotherapy ups survival in advanced liver cancer

(HealthDay)—STRIDE (Single tremelimumab Regular Interval durvalumab) is proposed as first-line therapy for unresectable hepatocellular carcinoma (uHCC), according to a study presented at the annual American Society of Clinical ...

page 1 from 3